Attenuation of monocyte chemotaxis-a novel anti-inflammatory mechanism of action for the cardio-protective hormone B-type natriuretic peptide

Journal of Cardiovascular Translational Research

Volumn 6, Issue 4, 2013, Pages 545-557

  Glezeva, Nadezhda ^a   Collier, Patrick ^a,b   Voon, Victor ^b   Ledwidge, Mark ^b   McDonald, Kenneth ^a,b   Watson, Chris ^a,b   Baugh, John ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

BNP; Calcium; Heart failure; Hypertension; Monocyte chemotaxis; NPRA; RhoA

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CALCIUM; CHEMOKINE RECEPTOR CCR2; MONOCYTE CHEMOTACTIC PROTEIN 1; NATRIURETIC PEPTIDE RECEPTOR A; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN;

AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CALCIUM TRANSPORT; CELL MIGRATION; CELL MOTILITY; CHEMOTAXIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HEART FAILURE; HEART PROTECTION; HUMAN; HUMAN CELL; HYPERTENSION; MALE; MOLECULAR DYNAMICS; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; SIGNAL TRANSDUCTION; UPREGULATION;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; CALCIUM; CELL LINE, TUMOR; CHEMOKINE CCL2; CHEMOTAXIS, LEUKOCYTE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MONOCYTES; NATRIURETIC PEPTIDE, BRAIN; RECEPTORS, ATRIAL NATRIURETIC FACTOR; RECEPTORS, CCR2; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84880510669     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-013-9456-1     Document Type: Article

References (77)

1. Levine, B.; Kalman, J.; Mayer, L.; Fillit, H. M.; & Packer, M. (1990). Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. The New England Journal of Medicine, 323, 236-241.
2. Torre-Amione, G.; Kapadia, S.; Lee, J.; Durand, J. B.; Bies, R. D.; Young, J. B.; et al. (1996). Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation, 93, 704-711.
3. Candia, A. M.; Villacorta, H.; Jr.; & Mesquita, E. T. (2007). Immune-inflammatory activation in heart failure. Arquivos Brasileiros de Cardiologia, 89(183-90), 201-208.
4. Nicoletti, A.; Heudes, D.; Mandet, C.; Hinglais, N.; Bariety, J.; & Michel, J. B. (1996). Inflammatory cells and myocardial fibrosis: spatial and temporal distribution in renovascular hypertensive rats. Cardiovascular Research, 32, 1096-1107.
5. Kuwahara, F.; Kai, H.; Tokuda, K.; Takeya, M.; Takeshita, A.; Egashira, K.; et al. (2004). Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension, 43, 739-745.
6. Westermann, D.; Lindner, D.; Kasner, M.; Zietsch, C.; Savvatis, K.; Escher, F.; et al. (2011). Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circulation: Heart Failure, 4, 44-52.
7. Kai, H.; Kuwahara, F.; Tokuda, K.; & Imaizumi, T. (2005). Diastolic dysfunction in hypertensive hearts: roles of perivascular inflammation and reactive myocardial fibrosis. Hypertension Research, 28, 483-490.
8. Xia, Y.; Lee, K.; Li, N.; Corbett, D.; Mendoza, L.; & Frangogiannis, N. G. (2009). Characterization of the inflammatory and fibrotic response in a mouse model of cardiac pressure overload. Histochemistry and Cell Biology, 131, 471-481.
9. Ammarguellat, F. Z.; Gannon, P. O.; Amiri, F.; & Schiffrin, E. L. (2002). Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rats: role of ET(A) receptors. Hypertension, 39, 679-684.
10. Nicoletti, A.; & Michel, J. B. (1999). Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors. Cardiovascular Research, 41, 532-543.
11. Yndestad, A.; Damas, J. K.; Oie, E.; Ueland, T.; Gullestad, L.; & Aukrust, P. (2006). Systemic inflammation in heart failure - the whys and wherefores. Heart Failure Reviews, 11, 83-92.
12. Gong, K. Z.; Song, G.; Spiers, J. P.; Kelso, E. J.; & Zhang, Z. G. (2007). Activation of immune and inflammatory systems in chronic heart failure: novel therapeutic approaches. International Journal of Clinical Practice, 61, 611-621.
13. Fildes, J. E.; Shaw, S. M.; Yonan, N.; & Williams, S. G. (2009). The immune system and chronic heart failure: is the heart in control? Journal of the American College of Cardiology, 53, 1013-1020.
14. Heymans, S.; Hirsch, E.; Anker, S. D.; Aukrust, P.; Balligand, J. L.; Cohen-Tervaert, J. W.; et al. (2009). Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 11, 119-129.
15. Steffens, S.; Montecucco, F.; & Mach, F. (2009). The inflammatory response as a target to reduce myocardial ischaemia and reperfusion injury. Thrombosis and Haemostasis, 102, 240-247.
16. Nishikimi, T.; Maeda, N.; & Matsuoka, H. (2006). The role of natriuretic peptides in cardioprotection. Cardiovascular Research, 69, 318-328.
17. Potter, L. R.; Abbey-Hosch, S.; Dickey, D. M.; D'Souza, S. P.; Davis, M.; Baxter, G. F.; et al. (2006). Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocrine Reviews, 27, 47-72.
18. D'Souza, S. P.; Davis, M.; & Baxter, G. F. (2004). Autocrine and paracrine actions of natriuretic peptides in the heart. Pharmacology and Therapeutics, 101, 113-129.
19. Hama, N.; Itoh, H.; Shirakami, G.; Nakagawa, O.; Suga, S.; Ogawa, Y.; et al. (1995). Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation, 92, 1558-1564.
20. Boomsma, F.; & van den Meiracker, A. H. (2001). Plasma A- and B-type natriuretic peptides: physiology, methodology and clinical use. Cardiovascular Research, 51, 442-449.
21. Cleland, J. G.; Taylor, J.; & Tendera, M. (2007). Prognosis in heart failure with a normal ejection fraction. The New England Journal of Medicine, 357, 829-830.
22. Maisel, A. S.; McCord, J.; Nowak, R. M.; Hollander, J. E.; Wu, A. H.; Duc, P.; et al. (2003). Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. Journal of the American College of Cardiology, 41, 2010-2017.
23. Phelan, D.; Watson, C.; Martos, R.; Collier, P.; Patle, A.; Donnelly, S.; et al. (2012). Modest elevation in BNP in asymptomatic hypertensive patients reflects sub-clinical cardiac remodeling, inflammation and extracellular matrix changes. PloS One, 7, e49259.
24. Maisel, A.; Mueller, C.; Adams, K.; Jr.; Anker, S. D.; Aspromonte, N.; Cleland, J. G.; et al. (2008). State of the art: using natriuretic peptide levels in clinical practice. European Journal of Heart Failure, 10, 824-839.
25. Fonarow, G. C. (2003). B-type natriuretic peptide: spectrum of application. Nesiritide (recombinant BNP) for heart failure. Heart Failure Reviews, 8, 321-325.
26. McMurray, J. J. (2012). Heart failure in 2011: heart failure therapy - technology to the fore. Nature Reviews Cardiology, 9, 73-74.
27. Chen, H. H.; Glockner, J. F.; Schirger, J. A.; Cataliotti, A.; Redfield, M. M.; & Burnett, J. C.; Jr. (2012). Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide. Journal of the American College of Cardiology, 60, 2305-2312.
28. Solomon, S. D.; Skali, H.; Bourgoun, M.; Fang, J.; Ghali, J. K.; Martelet, M.; et al. (2005). Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study. American Heart Journal, 150, 257-262.
29. Tamura, N.; Ogawa, Y.; Chusho, H.; Nakamura, K.; Nakao, K.; Suda, M.; et al. (2000). Cardiac fibrosis in mice lacking brain natriuretic peptide. Proceedings of the National Academy of Sciences of the United States of America, 97, 4239-4244.
30. Vellaichamy, E.; Khurana, M. L.; Fink, J.; & Pandey, K. N. (2005). Involvement of the NF-kappa B/matrix metalloproteinase pathway in cardiac fibrosis of mice lacking guanylyl cyclase/natriuretic peptide receptor A. Journal of Biological Chemistry, 280, 19230-19242.
31. Kuhn, M. (2005). Cardiac and intestinal natriuretic peptides: insights from genetically modified mice. Peptides, 26, 1078-1085.
32. Vellaichamy, E.; Kaur, K.; & Pandey, K. N. (2007). Enhanced activation of pro-inflammatory cytokines in mice lacking natriuretic peptide receptor-A. Peptides, 28, 893-899.
33. Giannessi, D.; Colotti, C.; Maltinti, M.; Del Ry, S.; Prontera, C.; Turchi, S.; et al. (2007). Circulating heat shock proteins and inflammatory markers in patients with idiopathic left ventricular dysfunction: their relationships with myocardial and microvascular impairment. Cell Stress & Chaperones, 12, 265-274.
34. Vaz Perez, A.; Doehner, W.; von Haehling, S.; Schmidt, H.; Zimmermann, AV.; Volk, HD.; et al. (2009). The relationship between tumor necrosis factor-alpha, brain natriuretic peptide and atrial natriuretic peptide in patients with chronic heart failure. International Journal of Cardiology 141(1):39-43.
35. Collier, P.; Watson, C. J.; Voon, V.; Phelan, D.; Jan, A.; Mak, G.; et al. (2011). Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? European Journal of Heart Failure, 13, 1087-1095.
36. Chen, H. H.; & Burnett, J. C.; Jr. (1999). The natriuretic peptides in heart failure: diagnostic and therapeutic potentials. Proceedings of the Association of American Physicians, 111, 406-416.
37. Macheret, F.; Heublein, D.; Costello-Boerrigter, L. C.; Boerrigter, G.; McKie, P.; Bellavia, D.; et al. (2012). Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP. Journal of the American College of Cardiology, 60, 1558-1565.
38. Kawakami, R.; Saito, Y.; Kishimoto, I.; Harada, M.; Kuwahara, K.; Takahashi, N.; et al. (2004). Overexpression of brain natriuretic peptide facilitates neutrophil infiltration and cardiac matrix metalloproteinase-9 expression after acute myocardial infarction. Circulation, 110, 3306-3312.
39. Kuhn, M.; Holtwick, R.; Baba, H. A.; Perriard, J. C.; Schmitz, W.; & Ehler, E. (2002). Progressive cardiac hypertrophy and dysfunction in atrial natriuretic peptide receptor (GC-A) deficient mice. Heart, 87, 368-374.
40. Oliver, P. M.; Fox, J. E.; Kim, R.; Rockman, H. A.; Kim, H. S.; Reddick, R. L.; et al. (1997). Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proceedings of the National Academy of Sciences of the United States of America, 94, 14730-14735.
41. Kapoun, A. M.; Liang, F.; O'Young, G.; Damm, D. L.; Quon, D.; White, R. T.; et al. (2004). B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circulation Research, 94, 453-461.
42. D'Souza, S. P.; & Baxter, G. F. (2003). B Type natriuretic peptide: a good omen in myocardial ischaemia? Heart, 89, 707-709.
43. Redfield, M. M.; Jacobsen, S. J.; Burnett, J. C.; Jr.; Mahoney, D. W.; Bailey, K. R.; & Rodeheffer, R. J. (2003). Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. Journal of the American Medical Association, 289, 194-202.
44. Parekh, N.; & Maisel, A. S. (2009). Utility of B-natriuretic peptide in the evaluation of left ventricular diastolic function and diastolic heart failure. Current Opinion in Cardiology, 24, 155-160.
45. Lubien, E.; DeMaria, A.; Krishnaswamy, P.; Clopton, P.; Koon, J.; Kazanegra, R.; et al. (2002). Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation, 105, 595-601.
46. Bennett, W. E.; & Cohn, Z. A. (1966). The isolation and selected properties of blood monocytes. The Journal of Experimental Medicine, 123, 145-160.
47. Huntley, B. K.; Sandberg, S. M.; Noser, J. A.; Cataliotti, A.; Redfield, M. M.; Matsuda, Y.; et al. (2006). BNP-induced activation of cGMP in human cardiac fibroblasts: interactions with fibronectin and natriuretic peptide receptors. Journal of Cellular Physiology, 209, 943-949.
48. Worthylake, R. A.; & Burridge, K. (2003). RhoA and ROCK promote migration by limiting membrane protrusions. Journal of Biological Chemistry, 278, 13578-13584.
49. de Lemos, J. A.; McGuire, D. K.; & Drazner, M. H. (2003). B-type natriuretic peptide in cardiovascular disease. Lancet, 362, 316-322.
50. Abulhul, E.; McDonald, K.; Martos, R.; Phelan, D.; Spiers, J. P.; Hennessy, M.; et al. (2012). Long-term statin therapy in patients with systolic heart failure and normal cholesterol: effects on elevated serum markers of collagen turnover, inflammation, and B-type natriuretic peptide. Clinical Therapeutics, 34, 91-100.
51. Pivovarova, O.; Gogebakan, O.; Kloting, N.; Sparwasser, A.; Weickert, M. O.; Haddad, I.; et al. (2012). Insulin up-regulates natriuretic peptide clearance receptor expression in the subcutaneous fat depot in obese subjects: a missing link between CVD risk and obesity? Journal of Clinical Endocrinology and Metabolism, 97, E731-E739.
52. Chiurchiu, V.; Izzi, V.; D'Aquilio, F.; Carotenuto, F.; Di Nardo, P.; & Baldini, P. M. (2008). Brain natriuretic peptide (BNP) regulates the production of inflammatory mediators in human THP-1 macrophages. Regulatory Peptides, 148, 26-32.
53. Shaw, SM.; Critchley, WR.; Puchalka, CM.; Williams, SG.; Yonan, N.; Fildes, JE. (2011). Brain natriuretic peptide induces CD8+ T cell death via a caspase 3 associated pathway - implications following heart transplantation. Transplant immunology 26(2-3):119-22.
54. Capers, Q.; Alexander, R. W.; Lou, P.; De Leon, H.; Wilcox, J. N.; Ishizaka, N.; et al. (1997). Monocyte chemoattractant protein-1 expression in aortic tissues of hypertensive rats. Hypertension, 30, 1397-1402.
55. Charo, I. F.; & Taubman, M. B. (2004). Chemokines in the pathogenesis of vascular disease. Circulation Research, 95, 858-866.
56. Ishibashi, M.; Hiasa, K.; Zhao, Q.; Inoue, S.; Ohtani, K.; Kitamoto, S.; et al. (2004). Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling. Circulation Research, 94, 1203-1210.
57. Frangogiannis, N. G.; Dewald, O.; Xia, Y.; Ren, G.; Haudek, S.; Leucker, T.; et al. (2007). Critical role of monocyte chemoattractant protein-1/CC chemokine ligand 2 in the pathogenesis of ischemic cardiomyopathy. Circulation, 115, 584-592.
58. Pryzwansky, K. B.; Kidao, S.; Wyatt, T. A.; Reed, W.; & Lincoln, T. M. (1995). Localization of cyclic GMP-dependent protein kinase in human mononuclear phagocytes. Journal of Leukocyte Biology, 57, 670-678.
59. Rolli-Derkinderen, M.; Sauzeau, V.; Boyer, L.; Lemichez, E.; Baron, C.; Henrion, D.; et al. (2005). Phosphorylation of serine 188 protects RhoA from ubiquitin/proteasome-mediated degradation in vascular smooth muscle cells. Circulation Research, 96, 1152-1160.
60. 2+. Handbook of Experimental Pharmacology 527-40.
61. Chen, J.; Crossland, R. F.; Noorani, M. M.; & Marrelli, S. P. (2009). Inhibition of TRPC1/TRPC3 by PKG contributes to NO-mediated vasorelaxation. American Journal of Physiology-Heart and Circulatory Physiology, 297, H417-H424.
62. Kaibuchi, K.; Kuroda, S.; & Amano, M. (1999). Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells. Annual Review of Biochemistry, 68, 459-486.
63. Honing, H.; van den Berg, T. K.; van der Pol, S. M.; Dijkstra, C. D.; van der Kammen, R. A.; Collard, J. G.; et al. (2004). RhoA activation promotes transendothelial migration of monocytes via ROCK. Journal of Leukocyte Biology, 75, 523-528.
64. Worthylake, R. A.; Lemoine, S.; Watson, J. M.; & Burridge, K. (2001). RhoA is required for monocyte tail retraction during transendothelial migration. The Journal of Cell Biology, 154, 147-160.
65. 2+ channels: new mechanism for depolarization-evoked mammalian arterial contraction. Circulation Research, 108, 1348-1357.
66. Evans, J. H.; & Falke, J. J. (2007). Ca2+ influx is an essential component of the positive-feedback loop that maintains leading-edge structure and activity in macrophages. Proceedings of the National Academy of Sciences of the United States of America, 104, 16176-16181.
67. Liu, D.; Scholze, A.; Zhu, Z.; Krueger, K.; Thilo, F.; Burkert, A.; et al. (2006). Transient receptor potential channels in essential hypertension. Journal of Hypertension, 24, 1105-1114.
68. Liu, D. Y.; Scholze, A.; Kreutz, R.; Wehland-von-Trebra, M.; Zidek, W.; Zhu, Z. M.; et al. (2007). Monocytes from spontaneously hypertensive rats show increased store-operated and second messenger-operated calcium influx mediated by transient receptor potential canonical type 3 channels. American Journal of Hypertension, 20, 1111-1118.
69. Liu, D.; Scholze, A.; Zhu, Z.; Kreutz, R.; Wehland-von-Trebra, M.; Zidek, W.; et al. (2005). Increased transient receptor potential channel TRPC3 expression in spontaneously hypertensive rats. American Journal of Hypertension, 18, 1503-1507.
70. Thilo, F.; Scholze, A.; Liu, D. Y.; Zidek, W.; & Tepel, M. (2008). Association of transient receptor potential canonical type 3 (TRPC3) channel transcripts with proinflammatory cytokines. Archives of Biochemistry and Biophysics, 471, 57-62.
71. Kinoshita, H.; Kuwahara, K.; Nishida, M.; Jian, Z.; Rong, X.; Kiyonaka, S.; et al. (2010). Inhibition of TRPC6 channel activity contributes to the antihypertrophic effects of natriuretic peptides-guanylyl cyclase-A signaling in the heart. Circulation Research, 106, 1849-1860.
72. 2+o)-sensing receptor in human peripheral blood monocytes. Biochemical and Biophysical Research Communications, 246, 501-506.
73. Olszak, I. T.; Poznansky, M. C.; Evans, R. H.; Olson, D.; Kos, C.; Pollak, M. R.; et al. (2000). Extracellular calcium elicits a chemokinetic response from monocytes in vitro and in vivo. The Journal of Clinical Investigation, 105, 1299-1305.
74. van Heerebeek, L.; Hamdani, N.; Falcao-Pires, I.; Leite-Moreira, AF.; Begieneman, MP.; Bronzwaer, JG.; et al. (2012). Low myocardial protein kinase g activity in heart failure with preserved ejection fraction. Circulation 126(7):830-839.
75. McMurray, JJ.; Adamopoulos, S.; Anker, SD.; Auricchio, A.; Bohm, M.; Dickstein K, et al. (2012). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal 33(14):1787-847.
76. Maisel, A. S.; Krishnaswamy, P.; Nowak, R. M.; McCord, J.; Hollander, J. E.; Duc, P.; et al. (2002). Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. The New England Journal of Medicine, 347, 161-167.
77. Spinetti, G.; Wang, M.; Monticone, R.; Zhang, J.; Zhao, D.; & Lakatta, E. G. (2004). Rat aortic MCP-1 and its receptor CCR2 increase with age and alter vascular smooth muscle cell function. Arteriosclerosis, Thrombosis, and Vascular Biology, 24, 1397-1402.